Shares of Cogent Biosciences, Inc. (NASDAQ:COGT – Get Free Report) have received a consensus recommendation of “Moderate Buy” from the seven brokerages that are covering the company, Marketbeat reports. Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $14.43.
A number of brokerages have recently issued reports on COGT. Wedbush restated a “neutral” rating and set a $11.00 price objective on shares of Cogent Biosciences in a research report on Tuesday, February 25th. Scotiabank initiated coverage on shares of Cogent Biosciences in a research note on Friday. They set a “sector outperform” rating and a $17.00 price target for the company. Robert W. Baird decreased their price target on Cogent Biosciences from $10.00 to $8.00 and set a “neutral” rating for the company in a report on Thursday, February 27th. JPMorgan Chase & Co. boosted their target price on Cogent Biosciences from $19.00 to $21.00 and gave the stock an “overweight” rating in a research note on Thursday, November 14th. Finally, HC Wainwright decreased their price objective on shares of Cogent Biosciences from $17.00 to $14.00 and set a “buy” rating for the company in a report on Tuesday, January 14th.
View Our Latest Research Report on Cogent Biosciences
Hedge Funds Weigh In On Cogent Biosciences
Cogent Biosciences Price Performance
Cogent Biosciences stock opened at $7.01 on Wednesday. The business has a 50 day moving average of $8.12 and a 200-day moving average of $9.49. The company has a market capitalization of $798.09 million, a P/E ratio of -2.83 and a beta of 1.81. Cogent Biosciences has a 1 year low of $5.73 and a 1 year high of $12.61.
About Cogent Biosciences
Cogent Biosciences, Inc, a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.
See Also
- Five stocks we like better than Cogent Biosciences
- What is a Dividend King?
- Is Myers Industries Poised for a Breakout?
- Technology Stocks Explained: Here’s What to Know About Tech
- Is BigBear.ai’s 25% Plunge a False Alarm or Fire Sale?
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- Broadcom Confirmed Its AI Outlook: Stock to Hit New Highs Soon
Receive News & Ratings for Cogent Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cogent Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.